Literature DB >> 16327332

High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART.

Berta Rodés1, Carlos Toro, Julie A Sheldon, Victoria Jiménez, Kamal Mansinho, Vincent Soriano.   

Abstract

We describe the emergence of the proV47A mutation in three out of five HIV-2-infected individuals failing lopinavir/ritonavir-based HAART. The appearance of such mutated variants resulted in high levels of phenotypic resistance to lopinavir, cross-resistance to indinavir, amprenavir, and hypersusceptibility to saquinavir. A search in HIV-2 databases revealed that proV47A is present in 8.6% of protease inhibitor (PI)-experienced patients but absent in all PI-naive patients. Its selection may be a common mutational pathway for developing resistance to lopinavir/ritonavir in HIV-2.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16327332     DOI： 10.1097/01.aids.0000196171.35056.6c

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  11 in total

1.  Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.

Authors:  Michel Ntemgwa; Bluma G Brenner; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.

Authors:  Dana N Raugi; Robert A Smith; Selly Ba; Macoumba Toure; Fatou Traore; Fatima Sall; Charlotte Pan; Lindsey Blankenship; Alexandra Montano; Julia Olson; Ndeye Mery Dia Badiane; James I Mullins; Nancy B Kiviat; Stephen E Hawes; Papa Salif Sow; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

3.  In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

Authors:  Sherie Masse; Xiaozhi Lu; Tatyana Dekhtyar; Liangjun Lu; Gennadiy Koev; Feng Gao; Hongmei Mo; Dale Kempf; Barry Bernstein; George J Hanna; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

4.  Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.

Authors:  Philip L Tzou; Diane Descamps; Soo-Yon Rhee; Dana N Raugi; Charlotte Charpentier; Nuno Taveira; Robert A Smith; Vicente Soriano; Carmen de Mendoza; Susan P Holmes; Geoffrey S Gottlieb; Robert W Shafer
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

5.  Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

Authors:  Kevin Peterson; Sabelle Jallow; Sarah L Rowland-Jones; Thushan I de Silva
Journal:  AIDS Res Treat       Date:  2011-02-09

6.  HIV-2 Protease resistance defined in yeast cells.

Authors:  Najoua Ben M'Barek; Gilles Audoly; Didier Raoult; Pablo Gluschankof
Journal:  Retrovirology       Date:  2006-09-06       Impact factor: 4.602

7.  HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.

Authors:  Joana Cavaco-Silva; Ana Abecasis; Ana Cláudia Miranda; José Poças; Jorge Narciso; Maria João Águas; Fernando Maltez; Isabel Almeida; Isabel Germano; António Diniz; Maria de Fátima Gonçalves; Perpétua Gomes; Celso Cunha; Ricardo Jorge Camacho
Journal:  PLoS One       Date:  2014-03-28       Impact factor: 3.240

Review 8.  Antiretroviral therapy response among HIV-2 infected patients: a systematic review.

Authors:  Didier K Ekouevi; Boris K Tchounga; Patrick A Coffie; Joseph Tegbe; Alexandra M Anderson; Geoffrey S Gottlieb; Marco Vitoria; François Dabis; Serge P Eholie
Journal:  BMC Infect Dis       Date:  2014-08-26       Impact factor: 3.090

9.  A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.

Authors:  Geoffrey S Gottlieb; Serge-Paul Eholié; John N Nkengasong; Sabelle Jallow; Sarah Rowland-Jones; Hilton C Whittle; Papa Salif Sow
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

10.  Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

Authors:  Jean Ruelle; François Roman; Anne-Thérèse Vandenbroucke; Christine Lambert; Katrien Fransen; Fedoua Echahidi; Denis Piérard; Chris Verhofstede; Kristel Van Laethem; Marie-Luce Delforge; Dolorès Vaira; Jean-Claude Schmit; Patrick Goubau
Journal:  BMC Infect Dis       Date:  2008-02-27       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.